BD Biosciences and Dynomics in Biomarker Alliance

BD Biosciences (Franklin Lakes, NJ, USA), a segment of Becton Dickinson and Company, has announced a licensing and research agreement with Dynomics BV (Rotterdam, The Netherlands) in the fields of leukemia and lymphoma. Under the terms of the agreement, BD has an exclusive worldwide license to specific intellectual property related to flow cytometry detection of fusion proteins. Financial terms were not disclosed.

Fusion proteins are unique proteins generated by a rearrangement of the chromosomes in a cell. Disease states such as leukemia are characterized by chromosomal rearrangements that generate changes in cellular composition. The proteins are important markers for diagnosing and monitoring leukemias.

Dynomics develops tests that provide diagnostic information on the classification of leukemia and lymphoma and information on the prognosis and staging of the disease. "Dynomics has made significant advances in fusion-protein identification and detection technology that fit well with our flow cytometry and bead-based platforms,” said William E. Rhodes, III, president of cell analysis, BD Biosciences. "This partnership and important new technology give BD the opportunity to advance technical solutions that can be applied in our core markets of ASR and reagent components used in leukemia and lymphoma testing.”

BD is a medical technology company that makes and sells medical devices, instrumented systems, and reagents. It is focused on enhancing the quality and speed of diagnosing infectious diseases, improving drug therapy, and advancing research and discovery of new drugs and vaccines.



Related Links:
BD Biosciences
Dynomics